View More Recent Stories

May 4, 2017 07:00AM Seres Therapeutics Reports First Quarter 2017 Financial Results and Provides Update on Operational Progress
May 1, 2017 04:00PM Seres Therapeutics Announces Participation at Two Upcoming Investor Conferences
Apr 28, 2017 04:00PM Seres Therapeutics to Host First Quarter 2017 Financial Results and Operational Progress Conference Call and Webcast on May 4, 2017
Mar 16, 2017 07:04AM Seres Therapeutics (MCRB) Announces New Phase 2 SER-109 Study in Patients with Multiply Recurrent C. Difficile
Mar 16, 2017 07:00AM Seres Therapeutics to Initiate New SER-109 Clinical Study
Mar 16, 2017 07:00AM Seres Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Operational Progress Update
Mar 13, 2017 07:00AM Seres Therapeutics to Host Fourth Quarter 2016 Financial Results and Operational Progress Conference Call and Webcast on March 16, 2017
Mar 2, 2017 07:00AM Seres Therapeutics to Present at the Cowen and Company 37th Annual Health Care Conference
Feb 3, 2017 07:00AM Seres Therapeutics Announces Participation at Two Upcoming Investor Conferences
Jan 31, 2017 07:18AM Seres Therapeutics (MCRB) Reports Key Findings from SER-109 Phase 2 Study Analyses
Jan 31, 2017 07:00AM Seres Therapeutics Announces Key Findings from SER-109 Phase 2 Study Analyses
Jan 30, 2017 04:00PM Seres Therapeutics to Host Conference Call and Webcast to Announce Key Findings from SER-109 Phase 2 Study Analyses
Nov 10, 2016 07:30AM Seres Therapeutics Reports Third Quarter 2016 Financial Results and Provides Operational Progress Update
Nov 4, 2016 08:00AM Seres Therapeutics to Host Third Quarter 2016 Financial Results and Operational Progress Conference Call and Webcast on November 10, 2016
Aug 11, 2016 07:00AM Seres Therapeutics Reports Second Quarter Financial Results and Provides Operational Progress Update
Aug 5, 2016 07:00AM Seres Therapeutics to Host Second Quarter 2016 Financial Results and Operational Progress Conference Call and Webcast on August 11, 2016
Jul 29, 2016 07:06AM Seres Therapeutics (MCRB) Primary Endpoint Not Achieved in SER-109 Phase 2 ECOSPOR Study
Jul 29, 2016 07:00AM Seres Therapeutics Announces Interim Results from SER-109 Phase 2 ECOSPOR Study in Multiply Recurrent Clostridium difficile Infection
Jul 12, 2016 07:03AM Seres Therapeutics (MCRB), Emulate Enter Collaboration to Advance Intestine-Chip Platform
Jul 12, 2016 07:00AM Seres Therapeutics and Emulate Announce Collaboration to Support the Development of Novel Microbiome Therapeutics for Inflammatory Bowel Disease and other Serious Conditions
Jul 7, 2016 07:00AM Seres Therapeutics Announces Initiation of a Phase 1b Clinical Trial of SER-262 for Primary Clostridium difficile Infection
Jun 22, 2016 08:30AM Seres Therapeutics Announces Collaboration with Massachusetts General Hospital to Identify Microbiome Therapeutics for Obesity and Metabolic Syndrome
Jun 20, 2016 01:00PM Seres Therapeutics Presents New Data at ASM Microbe 2016, including Characterization of SER-262, the Rationally-Designed, Fermented Microbiome Therapeutic Candidate for Primary Clostridium difficile I
Jun 6, 2016 07:17AM Seres Therapeutics (MCRB), May Clinical Enter Research Collaboration on Microbiome Therapeutic Candidates for Liver Diseases.
Jun 6, 2016 07:00AM Seres Therapeutics Announces Research Collaboration with Mayo Clinic to Identify Microbiome Therapeutics for Primary Sclerosing Cholangitis, Non-Alcoholic Steatohepatitis (NASH) and Other Liver Diseas
Jun 2, 2016 09:00AM Seres Therapeutics to Present at Goldman Sachs 37th Annual Global Healthcare Conference
May 17, 2016 08:00AM Seres Therapeutics to Present at the 2016 UBS Healthcare Conference
May 16, 2016 07:00AM Seres Therapeutics Announces Appointment of Thomas J. DesRosier as Chief Legal Officer and Executive Vice President
May 16, 2016 07:00AM Seres Therapeutics Reports First Quarter Financial Results and Provides Operational Progress Update
May 12, 2016 07:00AM Seres Therapeutics Announces Collaboration with University of Pennsylvania Researchers to Support the Development of Microbiome Therapeutics for Rare Genetic Metabolic Diseases and Inflammatory Bowel
May 12, 2016 07:00AM Seres Therapeutics Announces Broad Agreement with Memorial Sloan Kettering Cancer Center to Develop Microbiome Therapeutics for Hematopoietic Stem Cell Transplantation and Immuno-Oncology Treatment
May 9, 2016 08:00AM Seres Therapeutics to Host First Quarter 2016 Financial Results and Operational Progress Conference Call and Webcast on May 16, 2016
May 4, 2016 08:00AM Seres Therapeutics Announces Academic Collaborations to Support Development of Microbiome Therapeutics for Inflammatory Bowel Disease
May 3, 2016 08:00AM Seres Therapeutics to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
May 2, 2016 08:03AM Seres Therapeutics (MCRB) Achieves Target Enrollment of SER-109 Phase 2 Study
May 2, 2016 08:00AM Seres Therapeutics Announces Achievement of Target Enrollment of SER-109 Phase 2 Study for the Prevention of Recurrent Clostridium difficile Infection
Aug 19, 2015 10:00AM Seres Therapeutics, Inc. (Nasdaq: MCRB) to Ring The Nasdaq Stock Market Closing Bell
View More Recent Stories